Abstract:Huntington's disease is an inherited neurodegenerative disorder caused by a CAG repeat expansion that encodes a polyglutamine tract in the HTT protein. The mutant CAG repeat is unstable and expands in specific brain cells and peripheral tissues throughout life. Genes involved in the DNA mismatch repair pathways, known to act on expansion, have been identified as genetics modifiers, therefore, it is the rate of somatic CAG repeat expansion that drives the age of onset and rate of disease progression. In the context of an expanded CAG repeat, the pre-mRNA can be alternatively processed to generate the transcript, that encodes the aggregation prone and highly pathogenic HTT1a protein. This may be a mechanism through which somatic CAG repeat expansion exerts its pathogenic effects, as the longer the CAG repeat, the more and HTT1a is produced. The allelic series of knock-in mouse models: HdhQ20, HdhQ50, HdhQ80, HdhQ111, CAG140 and zQ175 with polyQ expansions of 20, 50, 80, 111 140 and ~190 can be used to model the molecular and cellular consequences of CAG repeat expansion within a single neuron. By western blot of cortical lysates, we found that mutant HTT levels decreased with increasing CAG repeat length; mutant HTT was only 23% and 10% of wild-type levels in CAG140 and zQ175 cortices, respectively. To identify the optimal bioassays for detecting the full-length HTT and HTT1a isoforms, we interrogated the pairwise combinations of seven well-characterized antibodies on both the HTRF and MSD platforms. In total we tested 32 HTRF and 32 MSD assays to detect full-length mutant HTT, HTT1a, total mutant HTT (full-length HTT and HTT1a) and total full-length HTT (mutant and wild type). None of these assays recapitulated the full-length mutant HTT levels as measured by western blot. We recommend using isoform- and species- specific assays that detect either full-length mutant HTT, HTT1a or wild-type HTT as opposed to those that detect more than one isoform simultaneously. Our finding that as the CAG repeat expands, full-length mutant HTT levels decrease, whilst and HTT1a levels increase has implications for therapeutic strategies. If mutant HTT levels in cells containing (CAG) are only 10% of wild-type, HTT-lowering strategies targeting full-length at sequences 3 prime to intron 1 will predominantly lower wild-type HTT, as mutant HTT levels in these cells are already depleted. These data support a therapeutic strategy that lowers and depletes levels of the HTT1a protein.

Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington disease models

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease

Efficient and Precise Processing of the Optimized Primary Artificial MicroRNA in a Huntingtin-Lowering Adeno-Associated Viral Gene Therapy In Vitro and in Mice and Nonhuman Primates

Lowering mutant huntingtin by small molecules relieves Huntington’s disease symptoms and progression

Progress in studies of gene therapy for Huntington's disease

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

Mutant HTT protein decreases with CAG repeat expansion: implications for therapeutics and bioassays.

Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease

Cas9-mediated Replacement of Expanded CAG Repeats in a Pig Model of Huntington’s Disease

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding

An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice

N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.

Effects of Exogenous Nub1 Expression in the Striatum of Hdq175/Q7 Mice

CRISPR/Cas9-mediated Gene Editing Ameliorates Neurotoxicity in Mouse Model of Huntington’s Disease

Splice modulators target PMS1 to reduce somatic expansion of the Huntington’s disease-associated CAG repeat

Huntingtin Exon 1 Deletion Does Not Alter the Subcellular Distribution of Huntingtin and Gene Transcription in Mice.

mRNA nuclear clustering leads to a difference in mutant huntingtin mRNA and protein silencing by siRNAs

The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model

A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease